Sapkota Kiran, Mao Zhihao, Synowicki Paul, Lieber Dillon, Liu Meng, Ikezu Tsuneya, Gautam Vivek, Monaghan Daniel T
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska (K.S., Z.M., P.S., D.L., M.L., D.T.M.); Departments of Pharmacology & Experimental Therapeutics and Neurology, School of Medicine, Boston University, Boston, Massachusetts (T.I.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (V.G.).
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska (K.S., Z.M., P.S., D.L., M.L., D.T.M.); Departments of Pharmacology & Experimental Therapeutics and Neurology, School of Medicine, Boston University, Boston, Massachusetts (T.I.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (V.G.)
J Pharmacol Exp Ther. 2016 Mar;356(3):702-11. doi: 10.1124/jpet.115.230391. Epub 2015 Dec 16.
The dissociative anesthetic ketamine elicits symptoms of schizophrenia at subanesthetic doses by blocking N-methyl-d-aspartate receptors (NMDARs). This property led to a variety of studies resulting in the now well-supported theory that hypofunction of NMDARs is responsible for many of the symptoms of schizophrenia. However, the roles played by specific NMDAR subunits in different symptom components are unknown. To evaluate the potential contribution of GluN2D NMDAR subunits to antagonist-induced cortical activation and schizophrenia symptoms, we determined the ability of ketamine to alter regional brain activity and gamma frequency band neuronal oscillations in wild-type (WT) and GluN2D-knockout (GluN2D-KO) mice. In WT mice, ketamine (30 mg/kg, i.p.) significantly increased [(14)C]-2-deoxyglucose ([(14)C]-2DG) uptake in the medial prefrontal cortex (mPFC), entorhinal cortex and other brain regions, and decreased activity in the somatosensory cortex and inferior colliculus. In GluN2D-KO mice, however, ketamine did not significantly increase [(14)C]-2DG uptake in any brain region examined, yet still decreased [(14)C]-2DG uptake in the somatosensory cortex and inferior colliculus. Ketamine also increased locomotor activity in WT mice but not in GluN2D-KO mice. In electrocorticographic analysis, ketamine induced a 111% ± 16% increase in cortical gamma-band oscillatory power in WT mice, but only a 15% ± 12% increase in GluN2D-KO mice. Consistent with GluN2D involvement in schizophrenia-related neurologic changes, GluN2D-KO mice displayed impaired spatial memory acquisition and reduced parvalbumin (PV)-immunopositive staining compared with control mice. These results suggest a critical role of GluN2D-containing NMDARs in neuronal oscillations and ketamine's psychotomimetic, dissociative effects and hence suggests a critical role for GluN2D subunits in cognition and perception.
解离性麻醉剂氯胺酮在亚麻醉剂量下通过阻断N-甲基-D-天冬氨酸受体(NMDARs)引发精神分裂症症状。这一特性引发了一系列研究,从而形成了如今得到充分支持的理论,即NMDARs功能低下是导致精神分裂症许多症状的原因。然而,特定NMDAR亚基在不同症状成分中所起的作用尚不清楚。为了评估谷氨酸N2D型NMDAR亚基对拮抗剂诱导的皮层激活和精神分裂症症状的潜在贡献,我们测定了氯胺酮改变野生型(WT)和谷氨酸N2D型基因敲除(GluN2D-KO)小鼠脑区活动和γ频段神经元振荡的能力。在野生型小鼠中,氯胺酮(30毫克/千克,腹腔注射)显著增加了内侧前额叶皮层(mPFC)、内嗅皮层和其他脑区的[¹⁴C]-2-脱氧葡萄糖([¹⁴C]-2DG)摄取,并降低了体感皮层和下丘的活动。然而,在GluN2D-KO小鼠中,氯胺酮在任何检测的脑区均未显著增加[¹⁴C]-2DG摄取,但仍降低了体感皮层和下丘的[¹⁴C]-2DG摄取。氯胺酮还增加了野生型小鼠的运动活性,但对GluN2D-KO小鼠没有影响。在脑电图分析中,氯胺酮使野生型小鼠皮层γ频段振荡功率增加了111%±16%,但在GluN2D-KO小鼠中仅增加了15%±12%。与谷氨酸N2D型参与精神分裂症相关神经变化一致,与对照小鼠相比,GluN2D-KO小鼠表现出空间记忆获取受损和小白蛋白(PV)免疫阳性染色减少。这些结果表明含谷氨酸N2D型的NMDARs在神经元振荡以及氯胺酮的拟精神病、解离效应中起关键作用,因此表明谷氨酸N2D型亚基在认知和感知中起关键作用。